Our second generation Optune System is smaller and less than half the weight of our first generation Optune System. See more on the innovation behind our redesigned Tumor Treating Fields delivery system.
Our Device Support Specialists (DSSs) work one-on-one with patients — educating them about the device, and providing technical support and personal contact with Novocure. Learn more about Amy Luton, one of our DSSs in Texas.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
publicationsWe have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.